A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis-Reference-Cited by-同舟云学术

A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis

Published:2009-06 Issue:6 Volume:44 Page:1078-1084
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Hagino Hiroshi,Nishizawa Yoshiki,Sone Teruki,Morii Hirotoshi,Taketani Yuji,Nakamura Toshitaka,Itabashi Akira,Mizunuma Hideaki,Ohashi Yasuo,Shiraki Masataka,Minamide Toshiomi,Matsumoto Toshio

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference27 articles.

1. Bisphosphonates—preclinical;Fleisch,2000

2. Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates;Dunford;J. Pharmacol. Exp. Ther.,2001

3. A randomized controlled trial with ONO-5920 (minodronate/YM529) in Japanese patients with postmenopausal osteoporosis;Morii;J. Bone. Miner. Res.,2002

4. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy;Sarkar;J. Bone. Miner. Res.,2002

5. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial;Bauer;J. Bone. Miner. Res.,2004

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta;BioMed Research International;2021-01-08

2. Morphological and Morphometrical Analyses of Fracture-Healing Sites of an Atypical Femoral Fracture in Patients with and without Long-Term Bisphosphonate Treatment for Osteoporosis: A Report of Two Cases;The Tohoku Journal of Experimental Medicine;2021

3. Minodronate in the treatment of osteoporosis;Medicine;2020-10-02

4. Synthesis and biological activities of drugs for the treatment of osteoporosis;European Journal of Medicinal Chemistry;2020-07

5. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study;Osteoporosis International;2020-01-28